Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)
NCT ID: NCT04510350
Last Updated: 2022-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2020-02-19
2022-03-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis
NCT05326048
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
NCT05072691
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period
NCT01112657
Seoul National University Hospital Systemic Sclerosis Cohort
NCT02819947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MS CIS+
Biomarkers analysis
Genetic analysis of regions of interest
Healthy volunteers
Biomarkers analysis
Genetic analysis of regions of interest
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biomarkers analysis
Genetic analysis of regions of interest
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Diagnosed with MS according to criteria 2017 at the time of their last visit.
* Non-opposition to participation in the study
* Having had at least one visit in the year following collection
* Follow-up for at least 1 year after collection.
* Having signed the OFSEP consent
* Age 18 years or older
* Having participated in the ABCD-SEP clinical trial promoted by the Rennes University Hospital (NCT03744351).
* Matched on age and sex to patients of interest in the OFSEP cohort
* Not having objected to participation in the study
Exclusion Criteria
Healthy volunteers :
* Persons of full age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laure Michel, Md
Role: PRINCIPAL_INVESTIGATOR
Rennes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Rennes
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC19_8880_CISCO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.